Neoplastic meningitis

Neurologist

Volumn 2, Issue 1, 1996, Pages 11-24

  Lesser, Glenn J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinomatous meningitis; Central nervous system malignancy; Central nervous system metastases; Leptomeningeal carcinomatosis; Meninges; Neoplastic meningitis; Spinal fluid

Indexed keywords

EID: 0003217548     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Lyons MK, Meyer FB. Cerebrospinal fluid physiology and the management of increased intracranial pressure [review]. Mayo Clin Proc 1990;65:684-707.
2. Bleyer WA. Current status of intrathecal chemotherapy for human meningeal neoplasms. Natl Cancer Inst Monogr 1977;46:171-8.
3. Chiro GD, Hammock MK, Bleyer WA. Spinal descent of cerebrospinal fluid in man. Neurology 1976;26:1-8.
4. Larson SM, Johnston GS, Ommaya AK, Jones AE, Di Chiro G. The radionuclide ventriculogram. JAMA 1973;224:853-7.
5. 111indium-DTPA CSF flow studies. Neurology 1991;41:1765-9.
6. Kokkoris CP. Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? [review]. Cancer 1983;51:154-60.
7. Rosen ST, Aisner J, Makuch RW, Matthews MJ, Ihde DC, Whitacre M, et al. Carcinomatous leptomeningitis in small cell lung cancer: A clinicopathologic review of the National Cancer Institute experience. Medicine (Baltimore) 1982;61:45-53.
8. Sze G. Diseases of the intracranial meninges: MR imaging features [review]. AJR Am J Roentgenol 1993;160:727-33.
9. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974;30:122-37.
10. Mirimanoff RO, Choi NC. Intradural spinal metastases in patients with posterior fossa brain metastases from various primary cancers. Oncology (Huntingt) 1987;44:232-6.
11. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 1982;49:759-72.
12. Siegal T, Sandbank U, Gabizon A, Mizrachi R, Ben-David E, Catane R. Alteration of blood-brain-CSF barrier in experimental meningeal carcinomatosis. A morphologic and adriamycin-penetration study. J Neurooncol 1987;4:233-42.
13. Pui MH, Langston JW, Arai Y. Gd-DTPA enhancement of CSF in meningeal carcinomatosis. J Comput Assist Tomogr 1993;17:940-4.
14. Eberth CJ. Zur Entwicklung des epitheliomas (cholesteatomas) dur pia und der lunge. Virchows Arch 1870;49:51-63.
15. Balis FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs [review]. Am J Pediatr Hematol Oncol 1989;11:74-86.
16. Walker RW. Neurologic complications of leukemia [review]]. Neurol Clin 1991;9:989-99.
17. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol 1978;19:579-92.
18. Nugent JL, Bunn PA Jr, Matthews MJ, Ihde DC, Cohen MH, Gazdar A, et al. CNS metastases in small cell bronchogenic carcinoma: Increasing frequency and changing pattern with lengthening survival. Cancer 1979;44:1885-93.
19. Jayson GC, Howell A, Harris M, Morgenstern G, Chang J, Ryder WD. Carcinomatous meningitis in patients with breast cancer. An aggressive disease variant. Cancer 1994;74:3135-41.
20. Yap HY, Yap BS, Tashima CK, DiStefano A, Blumenschein GR. Meningeal carcinomatosis in breast cancer. Cancer 1978;42:283-6.
21. Aroney RS, Dalley DN, Chan WK, Dell DR, Levi JA. Meningeal carcinomatosis in small cell carcinoma of the lung. Am J Med 1981;71:26-32.
22. Balducci L, Little DD, Khansur T, Steinberg MH. Carcinomatous meningitis in small cell lung cancer. Am J Med Sci 1984;287:31-3.
23. Aisner J, Ostrow S, Govindan S, Wiernik PH. Leptomeningeal carcinomatosis in small cell carcinoma of the lung. Med Pediatr Oncol 1981;9:47-59.
24. Nakagawa H, Murasawa A, Kubo S, Nakajima S, Nakajima Y, Izumoto S, et al. Diagnosis and treatment of patients with meningeal carcinomatosis. J Neurooncol 1992;13:81-9.
25. Gonzalez-Vitale JC, Garcia-Bunuel R. Meningeal carcinomatosis. Cancer 1976;37:2906-11.
26. Bunn PA Jr, Schein PS, Banks PM, DeVita VT Jr. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: Leukemia revisited. Blood 1976;47:3-10.
27. Ehya H, Hajdu SI, Melamed MR. Cytopathology of nonlymphoreticular neoplasms metastatic to the central nervous system. Acta Cytol 1981;25:599-610.
28. Pfeffer MR, Wygoda M, Siegal T. Leptomeningeal metastases - Treatment results in 98 consecutive patients. Isr J Med Sci 1988;24:611-8.
29. Shapiro WR, Posner JB, Ushio Y, Chemik NL, Young DF. Treatment of meningeal neoplasms. Cancer Treat Rep 1977;61:733-43.
30. Theodore WH, Gendelman S. Meningeal carcinomatosis. Arch Neurol 1981;38:696-9.
31. Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Rehman F, et al. Leptomeningeal metastases: Comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol 1990;9:225-9.
32. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology. Neurology 1979;29:1369-75.
33. Fisher MA, Weiss RB. Carcinomatous meningitis in gastrointestinal malignancies. South Med J 1979;72:930-2.
34. Tans RJ, Koudstaal J, Koehler PJ. Meningeal carcinomatosis as presenting symptom of a gallbladder carcinoma. Clin Neurol Neurosurg 1993;95:253-6.
35. Plaxe SC, Dottino PR, Lipsztein R, Dalton J, Cohen CJ. Clinical features and treatment outcome of patients with epithelial carcinoma of the ovary metastatic to the central nervous system. Obstet Gynecol 1990;75:278-81.
36. Bakri YN, Lee JH Jr, Lewis GC Jr, Lublin FD, Danoff B. Meningeal carcinomatosis complicating gynecologic malignancies: A literature review and report of a case [review]. Obstet Gynecol Surv 1983;38:1-5.
37. Raghavan D, Chye RW. Treatment of carcinomatous meningitis from transitional cell carcinoma of the bladder. Br J Urol 1991;67:438-40.
38. Crino PB, Sater RA, Sperling M, Katsetos CD. Renal cell carcinomatous meningitis: Pathologic and immunohistochemical features. Neurology 1995;45:189-91.
39. Eng C, Cunningham D, Quade BJ, Schwamm L, Kantoff PW, Skarin AT. Meningeal carcinomatosis from transitional cell carcinoma of the bladder. Cancer 1993;72:553-7.
40. Redman BG, Tapazoglou E, Al-Sarraf M. Meningeal carcinomatosis in head and neck cancer. Report of six cases and review of the literature. Cancer 1986;58:2656-61.
41. Meli FJ, Boccaleri CA, Manzitti J, Lylyk P. Meningeal dissemination of retinoblastoma: CT findings in eight patients. AJNR Am J Neuroradiol 1990;11:983-6.
42. Ringenberg QS, Francis R, Doll DC. Meningeal carcinomatosis as the presenting manifestation of tumors of unknown origin. Acta Cytol 1990;34:590-2.
43. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993;119:1093-104.
44. Arita N, Taneda M, Hayakawa T. Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 1994;126:84-92.
45. Davila G, Duyckaerts C, Lazareth JP, Poisson M, Delattre JY. Diffuse primary leptomeningeal gliomatosis [review]. J Neurooncol 1993;15:45-9.
46. Awad I, Bay JW, Rogers L. Leptomeningeal metastasis from supratentorial malignant gliomas. Neurosurgery 1986;19:247-51.
47. Yung WA, Horten BC, Shapiro WR. Meningeal gliomatosis: A review of 12. cases. Ann Neurol 1980;8:605-8.
48. Packer RJ, Siegel KR, Sutton LN, Litmann P, Bruce DA, Schut L. Leptomeningeal dissemination of primary central nervous system tumors of childhood. Ann Neurol 1985;18:217-21.
49. Siegal T, Mildworf B, Stein D, Melamed E. Leptomeningeal metastases: Reduction in regional cerebral blood flow and cognitive impairment. Ann Neurol 1985;17:100-2.
50. Watanabe M, Tanaka R, Takeda N. Correlation of MRI and clinical features in meningeal carcinomatosis. Neuroradiology 1993;35:512-5.
51. Klein P, Haley EC, Wooten GF, Vandenberg SR. Focal cerebral infarctions associated with perivascular tumor infiltrates in carcinomatous leptomeningeal metastases. Arch Neurol 1989;46:1149-52.
52. Chamberlain MC, Sandy AD, Press GA. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990;40:435-8.
53. Lee YY, Glass JP, Geoffray A, Wallace S. Cranial computed tomographic abnormalities in leptomeningeal metastasis. AJR Am J Roentgenol 1984;143:1035-9.
54. Jaeckle KA, Krol G, Posner JB. Evolution of computed tomographic abnormalities in leptomeningeal metastases. Ann Neurol 1985;17:85-9.
55. Krol G, Sze G, Malkin M, Walker R. MR of cranial and spinal meningeal carcinomatosis: Comparison with CT and myelography. AJR Am J Roentgenol 1988;151:583-8.
56. Sze G, Soletsky S, Bronen R, Krol G. MR imaging of the cranial meninges with emphasis on contrast enhancement and meningeal carcinomatosis. AJNR Am J Neuroradiol 1989;10:965-75.
57. Yousem DM, Patrone PM, Grossman RI. Leptomeningeal metastases: MR evaluation. J Comput Assist Tomogr 1990;14:255-61.
58. Schumacher DJ, Tien RD, Friedman H. Gadolinium enhancement of the leptomeninges caused by hydrocephalus: A potential mimic of leptomeningeal metastasis. AJNR Am J Neuroradiol 1994;15:639-41.
59. 111indium-DTPA ventriculography. Am J Med 1982;73:641-7.
60. Weisner B, Bernhardt W. Protein fractions of lumbar, cisternal, and ventricular cerebrospinal fluid. Separate areas of reference. J Neurol Sci 1978;37:205-14.
61. Wasserstrom WR, Schwartz MK, Fleisher M, Posner JB. Cerebrospinal fluid biochemical markers in central nervous system tumors: A review. Ann Clin Lab Sci 1981;11:239-51.
62. Yap BS, Yap HY, Fritsche HA, Blumenschein G, Bodey GP. CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer. JAMA 1980;244:1601-3.
63. Fleisher M, Wasserstrom WR, Schold SC, Schwartz MK, Posner JB. Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancer. Cancer 1981;47:2654-9.
64. Twijnstra A, Ongerboer de Visser BW, van Zanten AP, Hart AA, Nooyen, WJ. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J Neurooncol 1989;7:57-63.
65. van Zanten AP, Twijnstra A, Ongerboer de Visser BW, van Heerde P, Hart AA, et al. Cerebrospinal fluid tumour markers in patients treated for meningeal malignancy. J Neurol Neurosurg Psychiatry 1991;54:119-23.
66. Stewart DJ, Keating MJ, McCredie KB, Smith TL, Youness E, Murphy SG, et al. Natural history of central nervous system acute leukemia in adults. Cancer 1981;47:184-96.
67. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987;5:1655-62.
68. Sause WT, Crowleyj, Eyre HJ, Rivkin SE, Pugh RP, Quagliana JM, et al. Whole brain irradiation and intrathecal methotrexate in the treatment of solid tumor leptomeningeal metastases - A Southwest Oncology Group study. J Neurooncol 1988;6:107-12.
69. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993;11:561-9.
70. Grossman SA, Moynihan TJ. Neoplastic meningitis [review]. Neurol Clin 1991;9:843-56.
71. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975;195:73-83.
72. Miller KT, Wilkinson DS. Pharmacokinetics of methotrexate in the cerebrospinal fluid after intracerebroventricular administration in patients with meningeal carcinomatosis and altered cerebrospinal fluid flow dynamics. Ther Drug Monit 1989;11:231-7.
73. Collins JM. Pharmacokinetics of intraventricular administration. J Neurooncol 1983;1:283-91.
74. Blaney SM, Balis FM, Poplack DG. Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Huntingt) 1991;5:107-16.
75. Blaney SM, Balis FM, Poplack DG. Current pharmacological treatment approaches to central nervous system leukaemia. [review]. Drugs 1991;41:702-16.
76. Shapiro WR, Young DF, Mehta BM. Methotrexate: Distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975;293:161-6.
77. Larson SM, Schall GL, Di Chiro G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med 1971;12:555-7.
78. Bleyer WA, Poplack DG. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: Prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979;6:207-13.
79. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973;289:770-3.
80. Hryniuk WM, Bertino JR. Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates. J Clin Invest 1969;48:2140-55.
81. Sullivan MP, Humphrey GB, Vietti TJ, Haggard ME, Lee E. Superiority of conventional intrathecal methotrexate therapy with maintenance over intensive intrathecal methotrexate therapy, unmaintained, or radiotherapy (2000-2500 rads tumor dose) in treatment for meningeal leukemia. Cancer 1975;35:1066-73.
82. Sullivan MP, Vietti TJ, Haggard ME, Donaldson MH, Krall JM, Gehan EA. Remission maintenance therapy for meningeal leukemia: Intrathecal methotrexate vs. intravenous bis-nitrosourea. Blood 1971;38:680-8.
83. Strong JM, Collins JM, Lester C, Poplack DG. Pharmacokinetics of intraventricular and intravenous N,N′,N″-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans. Cancer Res 1986;46:6101-4.
84. Gutin PH, Weiss HD, Wiernik PH, Walker MD. Intrathecal N, N′, N″-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: Phase I-II study. Cancer 1976;38:1471-5.
85. Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: A phase II study. Cancer Treat Rep 1977;61:885-7.
86. Ho DH. Distribution of kinase and deaminase of 1-beta-D-arabinofuranosylcytosine in tissues of man and mouse. Cancer Res 1973;33:2816-20.
87. Lopez JA, Nassif E, Vannicola P, Krikorian JG, Agarwal RP. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neurooncol 1985;3:119-24.
88. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983;1:546-51.
89. Fulton DS, Levin VA, Gutin PH, Edwards MS, Seager ML, Stewart J, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol 1982;8:285-91.
90. Chamberlain MC, Khatibi S, Kim JC, Howell SD, Chatelut E, Kim S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch Neurol 1993;50:261-4.
91. Kim S, Kim DJ, Geyer MA, Howell SB. Multivesicular liposomes containing 1-beta-D-arabinofuranosylcytosine for slow-release intrathecal therapy.-Cancer Res 1987;47:3935-7.
92. Sullivan MP, Moon TE, Trueworthy R, Vietti TJ, Humphrey CD, Komp D. Combination intrathecal therapy for meningeal leukemia: Two versus three drugs. Blood 1977;50:471-9.
93. Schabet M, Ohneseit P, Buchholz R, Santo-Holtje L, Schmidberger H. Intrathecal ACNU treatment of B16 melanoma leptomeningeal metastasis in a new athymic rat model. J Neurooncol 1992;14:169-75.
94. Levin VA, Chamberlain M, Silver P, Rodriguez L, Prados M. Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol 1989;23:301-7.
95. Kochi M, Kuratsu J, Mihara Y, Takaki S, Seto H, Uemura S, et al. Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosou rea hydrochloride. Neurosurgery 1993;33:817-23.
96. Phillips PC, Than TT, Cork LC, Hilton J, Carson DS, Colvin OM, et al. Intrathecal 4-hydroperoxycyclophosphamide: Neurotoxicity, cerebrospinal fluid pharmacokinetics, and antitumor activity in a rabbit model of VX2 leptomeningeal carcinomatosis. Cancer Res 1992;52:6168-74.
97. Berg SL, Balis FM, Zimm S, Murphy RF, Holcenberg J, Sato J, et al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992;10:143-8.
98. Mencel PJ, DeAngelis LM, Motzer RJ. Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer 1994;73:1892-4.
99. Moseley RP, Benjamin JC, Ashpole RD, Sullivan NM, Bullimore JA, Coakham HB, et al. Carcinomatous meningitis: Antibody-guided therapy with I-131 HMFG1. J Neurol Neurosurg Psychiatry 1991;54:260-5.
100. Hall WA, Myklebust A, Godal A, Nesland JM, Fodstad O. In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma. Neurosurgery 1994;34:649-56.
101. Myklebust AT, Godal A, Fodstad O. Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer. Cancer Res 1994;54:2146-50.
102. Muraszko K, Sung C, Walbridge S, Greenfield L, Dedrick RL, Oldfield EH, et al. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents. Cancer Res 1993;53:3752-7.
103. Papadopoulos NEJ, Moser RP, Grimm E, Gerber D, Myers C, Leavens M, et al. Intrathecal use of recombinant interleukin-2 (rIL-2) in the treatment of leptomeningeal disease (LMD) from metastatic melanoma [abstract]. Proc Am Soc Clin Oncol 1995;14:412.
104. Ram Z, Walbridge S, Oshiro EM, Viola JJ, Chiang Y, Mueller SN, et al. Intrathecal gene therapy for malignant leptomeningeal neoplasia. Cancer Res 1994;54:2141-5.
105. Bleyer WA, Poplack DG, Simon RM. "Concentration × time" methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 1978;51:835-42.
106. Kay HE, Knapton PJ, O'Sullivan JP, Wells DG, Harris RF, Innes EM, et al. Encephalopathy in acute leukaemia associated with methotrexate therapy. Arch Dis Child 1972;47:344-54.
107. Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: A new classification. Cancer Treat Rep 1981;65(Suppl 1):89-98.
108. Burch PA, Grossman SA, Reinhard CS. Spinal cord penetration of intrathecally administered cytarabine and methotrexate: A quantitative autoradiographic study. J Natl Cancer Inst 1988;80:1211-6.
109. Lopez JA, Agarwal RP. Acute cerebellar toxicity after high-dose cytarabine associated with CNS accumulation of its metabolite, uracil arabinoside. Cancer Treat Rep 1984;68:1309-10.
110. Rubinstein LJ, Herman MM, Long TF, Wilbur JR. Disseminated necrotizing leukoencephalopathy: A complication of treated central nervous system leukemia and lymphoma. Cancer 1975;35:291-305.
111. Cruz-Sanchez FF, Artigas J, Cervos-Navarro J, Rossi ML, Ferszt R. Brain lesions following combined treatment with methotrexate and craniospinal irradiation. J Neurooncol 1991;10:165-71.
112. Liu HM, Maurer HS, Vongsvivut S, Conway JJ. Methotrexate encephalopathy. A neuropathologic study. Hum Pathol 1978;9:635-48.
113. Moss HA, Nannis ED, Poplack DG. The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia. Am J Med 1981;71:47-52.
114. Browne MJ, Dinndorf PA, Perek D, Commers J, Bleyer WA, Poplack DG, et al. Infectious complications of intraventricular reservoirs in cancer patients. Pediatr Infect Dis J 1987;6:182-9.
115. Siegal T, Pfeffer MR, Steiner I. Antibiotic therapy for infected Ommaya reservoir systems. Neurosurgery 1988;22:97-100.
116. Trump DL, Grossman SA, Thompson G, Murray K. CSF infections complicating the management of neoplastic meningitis. Clinical features and results of therapy. Arch Intern Med 1982;142:583-6.
117. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-7.